This is the text extract for 2010-04 Schedule Dispatch, browse documents here.

---

18 March 2010 April 2010 Pharmaceutical Schedule Dispatch This document is provided to pharmacists as an early notification of the changes to be announced in the April 2010 Update to the Pharmaceutical Schedule. Please notify PHARMAC (0800 66 00 50) to change or remove your contact details.

New listings · Bisacodyl (Dulcolax) suppos 10 mg – Only on a prescription (p’code: 270385) · Docusate sodium tab 50 mg (Laxofast 50) (p’code: 2350394) and tab 120 mg (Laxofast 120) (p’code: 2350386) · Ambrisentan (Volibris) tab 5 mg (p’code: 2349353) and 10 mg (p’code: 2349345) – Special Authority – Hospital pharmacy [HP1] · Hydrocortisone (Pharmacy Health) crm 1%, 100 g – Only on a prescription (p’code: 2339765) · Danazol (Azol) cap 200 mg – Retail pharmacy – Specialist (p’code: 2313006) · Topiramate (Arrow-Topiramate) tab 25 mg (p’code: 2350408), 50 mg (p’code: 2350416), 100 mg (p’code: 2350424) and 200 mg (p’code: 2350432) Changes to restrictions · Imiquimod (Aldara) crm 5% sachet – amended Special Authority criteria · Somatropin (Genotropin) inj cartridge 16 iu (5.3 mg) and 36 iu (12 mg) – amended presentation description · Nystatin (Nilstat) tab 500,000 u – Section 29 status removal · Influenza vaccine (Fluvax, Influvac and Vaxigrip) – amended access criteria · Alendronate for osteoporosis (Fosamax, Fosamax Plus) – amended access criteria · Gabapentin (Nupentin) cap 100 mg, 300 mg and 400 mg– amended Special Authority criteria · Vigabatrin (Sabril) tab 500 mg– amended Special Authority criteria · Travoprost (Travatan) eye drops 0.004% - additional subsidy by endorsement Increased subsidy

Chemical Bisacodyl Mitomycin C Chloramphenicol Presentation Suppos 5 mg Inj 10 mg Inj 1 mg for ECP Eye drops 0.5% Fully brands subsidised

Dulcolax Mitomycin-C Baxter Chlorsig

Decreased subsidy

Chemical Presentation Fully brands subsidised Partially subsidised brands

Dihydrocodeine tartrate Docusate sodium with sennosides Hydroxocobalamin Letrozole Promethazine hydrochloride

Tab long-acting 60 mg Tab 50 mg with total sennosides 8 mg Inj 1 mg per ml, 1 ml Tab 2.5 mg Oral liq 5 mg per 5 ml

DHC Continus Laxsol ABM Hydroxocobalamin Letara Promethazine Winthrop Elixir Neo-B12 Femara Phenergan

A342715 Page 1 of 2

---

Somatropin Tranexamic acid Travoprost Zidovudine (AZT)

Inj cartridge 16 iu (5.3 mg) Inj cartridge 36 iu (12 mg) Tab 500 mg Eye drops 0.004%

Genotropin Genotropin Cyklokapron Travatan*

Cap 100 mg Retrovir Oral liq 10 mg per ml Retrovir * Additional subsidy by endorsement available for Travatan eye drops

NB. For further details and magnitude of the above subsidy changes, please consult the online version of the Update to the Pharmaceutical Schedule at: www.pharmac.govt.nz/healthpros/Schedule.

Sumatriptan – smaller pack size continued availability

Arrow Pharmaceuticals has informed PHARMAC that it still has significant stock holdings of the smaller pack sizes of sumatriptan tab 50 mg (4 tablet pack) and 100 mg (2 tablet pack) due to be delisted from 1 May 2010. PHARMAC staff intend to recommend that these pack sizes continue to be listed in the Pharmaceutical Schedule at their current prices and subsidies until stock is exhausted. These pack sizes would, therefore, not be delisted from 1 May 2010 as initially notified.

Nestle special food – discontinuations

The following products are being discontinued by Nestle Healthcare Nutrition (these have not been included in the Update due to continued discussions between Nestle and PHARMAC) from the Pharmaceutical Schedule. It is expected that stock of the following products will run out within the next month:

Products to be delisted Resource Plus; all flavours Resource Diabetic; Strawberry Isosource HN 250 ml can and 1000 ml Fibersource HN 250 ml can and 1000 ml Isosource 1.5 250 ml and 1000 ml

Listed alternatives Alternative oral feed 1.5 Kcal/ml Resource Diabetic Vanilla Alternative enteral feed 1 Kcal/ml Alternative Enteral feed with fibre 1 Kcal/ml Alternative Enteral feed with fibre 1.5 Kcal/ml

*Note: The above table only refers to Nestle discontinuations of products currently listed in Section D of the Pharmaceutical Schedule

Special Foods listed under the same Special Authority criteria are interchangeable without a new Special Authority application being required.

A342715 Page 2 of 2